Free Trial
→ Trump to redistribute trillions of dollars (From Porter & Company) (Ad) Buy REPL Stock  Free REPL Stock Alerts

Replimune Group (REPL) Financials

Replimune Group logo
$8.85 +0.14 (+1.61%)
Closing price 04/23/2025 03:59 PM Eastern
Extended Trading
$8.84 -0.01 (-0.17%)
As of 04/23/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Replimune Group

Annual Income Statements for Replimune Group

This table shows Replimune Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -118 -174 -216
Consolidated Net Income / (Loss)		 -118 -174 -216
Net Income / (Loss) Continuing Operations		 -118 -174 -216
Total Pre-Tax Income 		-118 -174 -215
Total Operating Income		 -118 -177 -235
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 118 177 235
Selling, General & Admin Expense		 39 51 60
Research & Development Expense		 80 127 175
Total Other Income / (Expense), net		 0.28 3.08 19
Interest Expense		 2.22 4.16 6.66
Interest & Investment Income		 0.39 10 23
Other Income / (Expense), net		 2.11 -2.76 2.69
Income Tax Expense		 0.00 0.29 0.41
Basic Earnings per Share		 ($2.26) ($2.99) ($3.24)
Weighted Average Basic Shares Outstanding		 52.21M 58.21M 66.57M
Diluted Earnings per Share		 ($2.26) ($2.99) ($3.24)
Weighted Average Diluted Shares Outstanding		 52.21M 58.21M 66.57M
Weighted Average Basic & Diluted Shares Outstanding		 49.07M 57.78M 61.42M

Quarterly Income Statements for Replimune Group

This table shows Replimune Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Net Income / (Loss) Attributable to Common Shareholders		 -42 -43 -40 -49 -50 -60 -51 -55 -54 -53 -66
Consolidated Net Income / (Loss)		 -42 -43 -40 -49 -50 -60 -51 -55 -54 -53 -66
Net Income / (Loss) Continuing Operations		 -42 -43 -40 -49 -50 -60 -51 -55 -54 -53 -66
Total Pre-Tax Income 		-42 -43 -40 -49 -49 -60 -51 -55 -54 -53 -66
Total Operating Income		 -41 -42 -42 -53 -56 -64 -57 -59 -57 -59 -66
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 41 42 42 53 56 64 57 59 57 59 66
Selling, General & Admin Expense		 11 13 11 15 15 15 14 16 14 15 18
Research & Development Expense		 29 29 30 38 40 49 43 43 43 43 48
Total Other Income / (Expense), net		 -1.38 -1.52 1.94 4.04 6.29 3.59 5.89 3.61 3.60 5.86 0.25
Interest Expense		 0.55 0.55 1.49 1.57 1.66 1.50 1.55 1.95 1.96 1.97 1.98
Interest & Investment Income		 0.34 1.11 2.68 5.88 6.19 6.05 5.69 5.44 4.71 5.39 5.14
Other Income / (Expense), net		 -1.17 -2.09 0.75 -0.26 1.77 -0.97 1.76 0.13 0.84 2.44 -2.91
Income Tax Expense		 0.00 0.00 0.00 0.29 0.20 -0.20 0.47 -0.07 0.00 0.00 0.58
Basic Earnings per Share		 ($0.78) ($0.79) ($0.69) ($0.73) ($0.75) ($0.90) ($0.77) ($0.82) ($0.78) ($0.68) ($0.79)
Weighted Average Basic Shares Outstanding		 54.21M 54.77M 57.86M 58.21M 66.37M 66.58M 66.65M 66.57M 69.19M 78.57M 83.50M
Diluted Earnings per Share		 ($0.78) ($0.79) ($0.69) ($0.73) ($0.75) ($0.90) ($0.77) ($0.82) ($0.78) ($0.68) ($0.79)
Weighted Average Diluted Shares Outstanding		 54.21M 54.77M 57.86M 58.21M 66.37M 66.58M 66.65M 66.57M 69.19M 78.57M 83.50M
Weighted Average Basic & Diluted Shares Outstanding		 49.31M - 56.65M 57.78M 59.00M 59.06M 61.39M 61.42M 68.32M 68.42M 77.01M

Annual Cash Flow Statements for Replimune Group

This table details how cash moves in and out of Replimune Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -77 41 -72
Net Cash From Operating Activities		 -82 -128 -185
Net Cash From Continuing Operating Activities		 -82 -128 -185
Net Income / (Loss) Continuing Operations		 -118 -174 -216
Consolidated Net Income / (Loss)		 -118 -174 -216
Depreciation Expense		 2.15 2.45 2.66
Amortization Expense		 2.22 -5.64 -12
Non-Cash Adjustments To Reconcile Net Income		 27 37 36
Changes in Operating Assets and Liabilities, net		 4.96 13 4.36
Net Cash From Investing Activities		 -1.81 -143 97
Net Cash From Continuing Investing Activities		 -1.81 -143 97
Purchase of Property, Plant & Equipment		 -2.34 -2.27 -5.66
Purchase of Investments		 -256 -583 -490
Sale and/or Maturity of Investments		 256 443 592
Net Cash From Financing Activities		 6.60 311 16
Net Cash From Continuing Financing Activities		 6.60 311 16
Issuance of Debt		 0.00 28 15
Issuance of Common Equity		 0.00 280 0.00
Other Financing Activities, net		 6.60 3.08 1.28
Effect of Exchange Rate Changes		 0.82 -0.11 -0.09
Cash Interest Paid		 0.00 1.07 3.04
Cash Income Taxes Paid		 0.06 0.00 0.30

Quarterly Cash Flow Statements for Replimune Group

This table details how cash moves in and out of Replimune Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Net Change in Cash & Equivalents		 6.30 -23 118 -60 -40 -30 22 -23 77 -38 59
Net Cash From Operating Activities		 -33 -33 -29 -33 -49 -44 -47 -46 -49 -39 -51
Net Cash From Continuing Operating Activities		 -33 -33 -29 -33 -49 -44 -47 -46 -49 -39 -51
Net Income / (Loss) Continuing Operations		 -42 -43 -40 -49 -50 -60 -51 -55 -54 -53 -66
Consolidated Net Income / (Loss)		 -42 -43 -40 -49 -50 -60 -51 -55 -54 -53 -66
Depreciation Expense		 0.62 0.62 0.68 0.53 0.62 0.65 0.68 0.71 0.74 0.93 0.99
Amortization Expense		 0.24 -0.40 -1.62 -3.86 -4.09 -2.37 -3.06 -2.81 -2.79 -2.43 -1.79
Non-Cash Adjustments To Reconcile Net Income		 7.08 7.16 10 12 8.09 11 7.50 8.95 9.79 10 13
Changes in Operating Assets and Liabilities, net		 0.86 2.52 1.82 7.34 -3.65 7.07 -1.12 2.06 -3.13 5.47 3.71
Net Cash From Investing Activities		 5.32 0.04 -125 -23 7.36 13 54 23 30 0.46 -46
Net Cash From Continuing Investing Activities		 5.32 0.04 -125 -23 7.36 13 54 23 30 0.46 -46
Purchase of Property, Plant & Equipment		 -1.07 -0.40 -0.56 -0.25 -0.45 -1.75 -1.72 -1.74 -1.67 -2.08 -1.80
Purchase of Investments		 -61 -133 -240 -150 -169 -112 -100 -108 -105 -89 -137
Sale and/or Maturity of Investments		 67 134 116 127 177 126 156 133 137 92 93
Net Cash From Financing Activities		 33 7.42 271 -0.08 1.11 0.44 15 -0.13 97 -0.04 156
Net Cash From Continuing Financing Activities		 33 7.42 271 -0.08 1.11 0.44 15 -0.13 97 -0.04 156
Issuance of Common Equity		 31 6.40 243 -0.25 0.00 - - - 97 - 156
Other Financing Activities, net		 1.49 1.02 0.40 0.17 1.11 0.44 -0.13 -0.13 -0.07 -0.04 -0.10
Effect of Exchange Rate Changes		 1.92 2.44 -0.01 -4.45 0.01 -0.02 -0.03 -0.06 -0.04 0.06 -0.15
Cash Interest Paid		 0.00 - - 1.07 0.65 0.69 0.69 1.01 1.05 1.81 0.29
Cash Income Taxes Paid		 - - - - - - - - - - 0.11

Annual Balance Sheets for Replimune Group

This table presents Replimune Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 461 647 488
Total Current Assets		 404 593 434
Cash & Equivalents		 106 147 74
Short-Term Investments		 290 437 346
Prepaid Expenses		 5.27 6.28 8.08
Other Current Assets		 3.06 2.94 4.92
Plant, Property, & Equipment, net		 7.93 7.48 10
Total Noncurrent Assets		 49 47 44
Noncurrent Note & Lease Receivables		 42 40 37
Other Noncurrent Operating Assets		 7.19 6.84 6.34
Total Liabilities & Shareholders' Equity		 461 647 488
Total Liabilities		 50 91 113
Total Current Liabilities		 21 34 40
Accounts Payable		 3.73 5.36 2.58
Accrued Expenses		 13 25 34
Other Current Liabilities		 3.63 3.76 3.88
Total Noncurrent Liabilities		 29 57 73
Long-Term Debt		 - 29 45
Capital Lease Obligations		 - 24 23
Other Noncurrent Operating Liabilities		 29 4.86 4.56
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 411 555 375
Total Preferred & Common Equity		 411 555 375
Total Common Equity		 411 555 375
Common Stock		 723 1,035 1,071
Retained Earnings		 -311 -485 -701
Accumulated Other Comprehensive Income / (Loss)		 -0.97 5.73 4.86

Quarterly Balance Sheets for Replimune Group

This table presents Replimune Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Total Assets		 459 679 604 562 533 535 498 604
Total Current Assets		 402 624 550 508 479 480 443 548
Cash & Equivalents		 112 207 106 76 98 152 113 172
Short-Term Investments		 283 410 433 421 369 317 319 364
Prepaid Expenses		 4.04 5.59 7.90 8.51 8.52 6.26 8.53 7.97
Other Current Assets		 2.83 2.00 3.05 2.90 4.30 4.93 2.05 3.07
Plant, Property, & Equipment, net		 8.27 7.68 7.62 8.45 9.47 11 13 14
Total Noncurrent Assets		 49 47 46 46 44 43 43 42
Noncurrent Note & Lease Receivables		 41 40 39 38 38 37 36 35
Other Noncurrent Operating Assets		 7.73 6.64 7.18 7.33 6.45 6.61 6.95 7.02
Total Liabilities & Shareholders' Equity		 459 679 604 562 533 535 498 604
Total Liabilities		 49 83 90 97 111 109 117 121
Total Current Liabilities		 20 26 32 40 39 36 44 48
Accounts Payable		 4.48 3.65 4.88 4.37 3.90 0.86 8.41 7.19
Accrued Expenses		 12 19 24 32 31 31 31 37
Other Current Liabilities		 3.62 3.66 3.80 3.82 3.86 3.90 3.96 3.94
Total Noncurrent Liabilities		 29 57 58 57 73 73 73 73
Long-Term Debt		 - 28 29 29 44 45 46 46
Capital Lease Obligations		 24 24 24 24 24 23 23 23
Other Noncurrent Operating Liabilities		 4.54 4.27 4.87 4.52 4.75 4.39 4.29 4.49
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 410 595 514 465 422 426 381 482
Total Preferred & Common Equity		 410 595 514 465 422 426 381 482
Total Common Equity		 410 595 514 465 422 426 381 482
Common Stock		 763 1,028 1,045 1,055 1,063 1,177 1,186 1,351
Retained Earnings		 -353 -436 -535 -595 -646 -755 -808 -874
Accumulated Other Comprehensive Income / (Loss)		 0.52 3.74 3.97 5.49 4.73 4.32 3.63 6.16

Annual Metrics and Ratios for Replimune Group

This table displays calculated financial ratios and metrics derived from Replimune Group's official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -49.66% -63.66% -32.08%
EBIT Growth		 -49.34% -54.77% -29.05%
NOPAT Growth		 -47.98% -49.67% -32.58%
Net Income Growth		 -45.96% -47.65% -23.82%
EPS Growth		 -29.14% -32.30% -8.36%
Operating Cash Flow Growth		 -33.87% -55.82% -44.84%
Free Cash Flow Firm Growth		 0.00% -159.46% -21.81%
Invested Capital Growth		 -66.98% 57.44% -10.03%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -2,630.80% -16,530.25% -1.74%
EBIT Q/Q Growth		 0.00% 0.00% -2.37%
NOPAT Q/Q Growth		 0.00% 0.00% -2.51%
Net Income Q/Q Growth		 0.00% 0.00% -2.78%
EPS Q/Q Growth		 0.00% 0.00% -2.86%
Operating Cash Flow Q/Q Growth		 -8.49% -8.69% -7.77%
Free Cash Flow Firm Q/Q Growth		 0.00% -841.89% -6.47%
Invested Capital Q/Q Growth		 -10.17% -22.03% -4.84%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.17% 100.19%
Interest Burden Percent		 101.58% 96.75% 92.81%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -25.94% -36.06% -46.42%
Cash Return on Invested Capital (CROIC)		 -163.27% -662.96% -695.10%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -25.94% -36.06% -46.42%
Return on Equity Simple (ROE_SIMPLE)		 -28.70% -31.39% -57.62%
Net Operating Profit after Tax (NOPAT)		 -83 -124 -164
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.31% -10.87% -11.65%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -116 -180 -232
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -112 -183 -242
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.95 1.80 1.34
Price to Tangible Book Value (P/TBV)		 1.95 1.80 1.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 26.07 19.16 6.76
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.09 0.18
Long-Term Debt to Equity		 0.00 0.09 0.18
Financial Leverage		 -0.93 -0.96 -0.95
Leverage Ratio		 1.10 1.15 1.22
Compound Leverage Factor		 1.12 1.11 1.13
Debt to Total Capital		 0.00% 8.65% 15.41%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 8.65% 15.41%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 91.35% 84.59%
Debt to EBITDA		 0.00 -0.29 -0.28
Net Debt to EBITDA		 0.00 2.90 1.46
Long-Term Debt to EBITDA		 0.00 -0.29 -0.28
Debt to NOPAT		 0.00 -0.42 -0.42
Net Debt to NOPAT		 0.00 4.28 2.14
Long-Term Debt to NOPAT		 0.00 -0.42 -0.42
Altman Z-Score		 8.85 5.64 0.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 19.46 17.52 10.72
Quick Ratio		 19.06 17.25 10.40
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -51 -133 -162
Operating Cash Flow to CapEx		 -3,517.98% -5,640.97% -3,275.64%
Free Cash Flow to Firm to Interest Expense		 -23.04 -31.95 -24.31
Operating Cash Flow to Interest Expense		 -36.97 -30.78 -27.85
Operating Cash Flow Less CapEx to Interest Expense		 -38.02 -31.33 -28.70
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 16 25 22
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -32 8.95 -2.46
Enterprise Value (EV)		 406 470 149
Market Capitalization		 802 1,001 502
Book Value per Share		 $8.71 $9.80 $6.10
Tangible Book Value per Share		 $8.71 $9.80 $6.10
Total Capital		 411 608 443
Total Debt		 0.00 53 68
Total Long-Term Debt		 0.00 53 68
Net Debt		 -396 -531 -352
Capital Expenditures (CapEx)		 2.34 2.27 5.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -25 -27
Debt-free Net Working Capital (DFNWC)		 383 559 393
Net Working Capital (NWC)		 383 559 393
Net Nonoperating Expense (NNE)		 35 50 51
Net Nonoperating Obligations (NNO)		 -396 -531 -352
Total Depreciation and Amortization (D&A)		 4.37 -3.19 -9.67
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.26) ($2.99) ($3.24)
Adjusted Weighted Average Basic Shares Outstanding		 52.21M 58.21M 66.57M
Adjusted Diluted Earnings per Share		 ($2.26) ($2.99) ($3.24)
Adjusted Weighted Average Diluted Shares Outstanding		 52.21M 58.21M 66.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.07M 57.78M 61.42M
Normalized Net Operating Profit after Tax (NOPAT)		 -83 -124 -164
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -52.27 -43.23 -34.85
NOPAT to Interest Expense		 -37.26 -29.80 -24.68
EBIT Less CapEx to Interest Expense		 -53.32 -43.78 -35.70
NOPAT Less CapEx to Interest Expense		 -38.31 -30.34 -25.53
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Replimune Group

This table displays calculated financial ratios and metrics derived from Replimune Group's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -60.43% -40.11% -43.17% -5,891.81% -39.27% -53.07% -36.70% -7.32% -2.13% 12.82% -21.98%
EBIT Growth		 -56.62% -47.50% -39.96% 0.00% -28.15% -48.40% -34.02% -10.07% -4.90% 12.84% -25.82%
NOPAT Growth		 -49.29% -42.17% -40.18% 0.00% -36.14% -53.52% -35.82% -10.87% -3.09% 7.70% -16.77%
Net Income Growth		 -54.71% 0.00% -33.75% 0.00% -17.28% -39.31% -28.80% -11.85% -8.51% 11.64% -29.77%
EPS Growth		 -47.17% 0.00% -21.05% 0.00% 3.85% -13.92% -11.59% -12.33% -4.00% 24.44% -2.60%
Operating Cash Flow Growth		 -82.67% -44.64% 0.00% -45.39% -45.23% -31.26% -64.83% -40.77% -1.19% 11.36% -7.62%
Free Cash Flow Firm Growth		 -237.66% 51.98% -184.50% -245.71% 42.76% -783.71% 27.60% 16.02% -40.96% 42.35% -20.53%
Invested Capital Growth		 90.84% -100.00% 81.39% 57.44% -29.92% 0.00% -26.29% -10.03% -6.87% -15.11% -36.55%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -4,315.05% -5.51% 3.77% -35.32% -1.35% -15.97% 14.06% -6.24% 3.55% 1.01% -20.25%
EBIT Q/Q Growth		 0.00% -3.85% 6.39% -30.29% -1.17% -20.26% 15.46% -7.01% 3.58% 0.08% -22.03%
NOPAT Q/Q Growth		 0.00% -1.72% -0.12% -27.30% -5.01% -14.70% 11.42% -3.92% 2.36% -2.70% -12.06%
Net Income Q/Q Growth		 0.00% -2.01% 7.92% -24.06% -0.64% -21.17% 14.86% -7.74% 2.37% 1.33% -25.04%
EPS Q/Q Growth		 0.00% -1.28% 12.66% -5.80% -2.74% -20.00% 14.44% -6.49% 4.88% 12.82% -16.18%
Operating Cash Flow Q/Q Growth		 -48.31% 0.73% 13.91% -14.72% -48.15% 10.29% -8.11% 2.03% -6.50% 21.41% -31.25%
Free Cash Flow Firm Q/Q Growth		 -250.05% 84.26% -479.44% -6.45% 41.05% -143.05% 52.53% -23.49% 1.07% 0.60% 0.75%
Invested Capital Q/Q Growth		 153.56% -100.00% 0.00% -22.03% 12.88% -23.11% 8.93% -4.84% 16.85% -29.91% -18.58%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.59% 100.41% 99.67% 100.93% 99.88% 100.00% 100.00% 100.87%
Interest Burden Percent		 100.50% 98.71% 97.10% 91.91% 91.60% 92.98% 92.45% 94.06% 95.13% 93.94% 95.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.91% 0.00% 0.00% -36.06% -39.29% -85.36% -41.29% -46.42% -46.79% -50.32% -50.50%
Cash Return on Invested Capital (CROIC)		 -369.09% 200.00% -57.85% -662.96% -364.72% -1,608.51% -556.65% -695.10% -612.31% -807.64% -845.98%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -29.91% 0.00% 0.00% -36.06% -39.29% -85.36% -41.29% -46.42% -46.79% -50.32% -50.50%
Return on Equity Simple (ROE_SIMPLE)		 -32.41% 0.00% 0.00% 0.00% -35.33% -42.68% -49.81% 0.00% -51.59% -55.84% -47.32%
Net Operating Profit after Tax (NOPAT)		 -29 -29 -29 -37 -39 -45 -40 -41 -40 -41 -46
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.29% -6.42% -2.14% -2.62% -2.47% -6.92% -2.40% -3.16% -3.07% -2.93% -4.65%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -8.08% - - - -8.38%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -42 -44 -41 -53 -54 -65 -55 -59 -57 -56 -69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -41 -43 -42 -57 -57 -67 -57 -61 -59 -58 -70
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.09 0.00 2.25 1.80 2.61 2.17 1.18 1.34 1.30 1.96 1.72
Price to Tangible Book Value (P/TBV)		 2.09 0.00 2.25 1.80 2.61 2.17 1.18 1.34 1.30 1.96 1.72
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 12.33 0.00 24.72 19.16 30.90 26.57 4.29 6.76 5.90 21.33 24.54
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 697.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 39.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.06 0.00 0.09 0.09 0.10 0.11 0.16 0.18 0.16 0.18 0.14
Long-Term Debt to Equity		 0.06 0.00 0.09 0.09 0.10 0.11 0.16 0.18 0.16 0.18 0.14
Financial Leverage		 -0.93 -0.95 -0.95 -0.96 -0.93 -0.95 -0.95 -0.95 -0.94 -0.95 -0.96
Leverage Ratio		 1.11 1.10 1.13 1.15 1.15 1.21 1.19 1.22 1.21 1.25 1.26
Compound Leverage Factor		 1.11 1.09 1.09 1.05 1.05 1.12 1.10 1.15 1.15 1.18 1.20
Debt to Total Capital		 5.59% 0.00% 8.10% 8.65% 9.31% 10.21% 13.89% 15.41% 13.83% 15.25% 12.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 5.59% 0.00% 8.10% 8.65% 9.31% 10.21% 13.89% 15.41% 13.83% 15.25% 12.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 94.41% 0.00% 91.90% 91.35% 90.69% 89.79% 86.11% 84.59% 86.17% 84.75% 87.51%
Debt to EBITDA		 -0.19 0.00 47.11 -0.29 -0.26 -0.24 -0.29 -0.28 -0.28 -0.29 -0.28
Net Debt to EBITDA		 2.91 0.00 -506.19 2.90 2.44 2.00 1.68 1.46 1.65 1.55 1.89
Long-Term Debt to EBITDA		 -0.19 0.00 47.11 -0.29 -0.26 -0.24 -0.29 -0.28 -0.28 -0.29 -0.28
Debt to NOPAT		 -0.26 0.00 0.00 -0.42 -0.39 -0.35 -0.42 -0.42 -0.41 -0.42 -0.41
Net Debt to NOPAT		 4.02 0.00 0.00 4.28 3.62 2.96 2.48 2.14 2.42 2.24 2.77
Long-Term Debt to NOPAT		 -0.26 0.00 0.00 -0.42 -0.39 -0.35 -0.42 -0.42 -0.41 -0.42 -0.41
Altman Z-Score		 10.09 0.00 9.63 6.29 8.45 5.37 1.64 1.22 1.73 2.16 2.69
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.79 0.00 23.58 17.52 17.06 12.76 12.40 10.72 13.46 10.11 11.43
Quick Ratio		 19.45 0.00 23.29 17.25 16.72 12.47 12.07 10.40 13.15 9.87 11.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -47 -7.46 -43 -46 -27 -66 -31 -39 -38 -38 -38
Operating Cash Flow to CapEx		 -3,132.49% -8,386.36% -5,151.17% -13,066.14% -10,821.38% -2,485.18% -2,741.30% -2,653.22% -2,945.90% -1,854.08% -2,817.39%
Free Cash Flow to Firm to Interest Expense		 -85.89 -13.57 -29.05 -29.34 -16.36 -44.06 -20.18 -19.81 -19.52 -19.31 -19.08
Operating Cash Flow to Interest Expense		 -60.61 -60.38 -19.20 -20.90 -29.29 -29.12 -30.36 -23.65 -25.09 -19.62 -25.64
Operating Cash Flow Less CapEx to Interest Expense		 -62.54 -61.10 -19.57 -21.06 -29.56 -30.29 -31.47 -24.54 -25.94 -20.68 -26.55
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 39 0.00 31 25 28 21 23 22 26 18 15
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 19 -22 14 8.95 -12 21 -8.27 -2.46 -1.90 -3.22 -8.47
Enterprise Value (EV)		 487 852 777 470 855 566 100 149 152 385 361
Market Capitalization		 858 852 1,341 1,001 1,342 1,009 498 502 553 749 829
Book Value per Share		 $8.36 $0.00 $10.29 $9.80 $8.90 $7.88 $7.14 $6.10 $6.94 $5.58 $7.05
Tangible Book Value per Share		 $8.36 $0.00 $10.29 $9.80 $8.90 $7.88 $7.14 $6.10 $6.94 $5.58 $7.05
Total Capital		 435 0.00 648 608 567 518 490 443 495 450 551
Total Debt		 24 0.00 52 53 53 53 68 68 68 69 69
Total Long-Term Debt		 24 0.00 52 53 53 53 68 68 68 69 69
Net Debt		 -371 0.00 -564 -531 -486 -444 -398 -352 -401 -363 -468
Capital Expenditures (CapEx)		 1.07 0.40 0.56 0.25 0.45 1.75 1.72 1.74 1.67 2.08 1.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 0.00 -19 -25 -21 -28 -26 -27 -24 -33 -37
Debt-free Net Working Capital (DFNWC)		 382 0.00 597 559 518 468 441 393 445 399 500
Net Working Capital (NWC)		 382 0.00 597 559 518 468 441 393 445 399 500
Net Nonoperating Expense (NNE)		 14 14 11 12 11 15 12 14 14 12 20
Net Nonoperating Obligations (NNO)		 -371 0.00 -564 -531 -486 -444 -398 -352 -401 -363 -468
Total Depreciation and Amortization (D&A)		 0.86 0.21 -0.94 -3.33 -3.47 -1.71 -2.38 -2.11 -2.05 -1.50 -0.80
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.78) $0.00 ($0.69) ($0.73) ($0.75) ($0.90) ($0.77) ($0.82) ($0.78) ($0.68) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding		 54.21M 0.00 57.86M 58.21M 66.37M 66.58M 66.65M 66.57M 69.19M 78.57M 83.50M
Adjusted Diluted Earnings per Share		 ($0.78) $0.00 ($0.69) ($0.73) ($0.75) ($0.90) ($0.77) ($0.82) ($0.78) ($0.68) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 54.21M 0.00 57.86M 58.21M 66.37M 66.58M 66.65M 66.57M 69.19M 78.57M 83.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.31M 0.00 56.65M 57.78M 59.00M 59.06M 61.39M 61.42M 68.32M 68.42M 77.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -29 -29 -29 -37 -39 -45 -40 -41 -40 -41 -46
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -76.17 -79.39 -27.45 -33.94 -32.48 -43.28 -35.30 -30.03 -28.84 -28.68 -34.85
NOPAT to Interest Expense		 -51.84 -52.92 -19.57 -23.64 -23.48 -29.85 -25.50 -21.07 -20.49 -20.95 -23.36
EBIT Less CapEx to Interest Expense		 -78.10 -80.11 -27.82 -34.10 -32.75 -44.46 -36.40 -30.92 -29.69 -29.74 -35.76
NOPAT Less CapEx to Interest Expense		 -53.77 -53.64 -19.94 -23.80 -23.75 -31.02 -26.61 -21.96 -21.34 -22.00 -24.27
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Replimune Group's Financials

When does Replimune Group's financial year end?

According to the most recent income statement we have on file, Replimune Group's fiscal year ends in March. Their fiscal year 2024 ended on March 31, 2024.

How has Replimune Group's net income changed over the last 2 years?

Replimune Group's net income appears to be on an upward trend, with a most recent value of -$215.79 million in 2024, rising from -$118.04 million in 2022. The previous period was -$174.28 million in 2023.

What is Replimune Group's operating income?
Replimune Group's total operating income in 2024 was -$234.77 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $234.77 million
How has Replimune Group revenue changed over the last 2 years?

Over the last 2 years, Replimune Group's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Replimune Group have?

Replimune Group's total liabilities were at $113.21 million at the end of 2024, a 24.0% increase from 2023, and a 126.6% increase since 2022.

How much cash does Replimune Group have?

In the past 2 years, Replimune Group's cash and equivalents has ranged from $74.46 million in 2024 to $146.59 million in 2023, and is currently $74.46 million as of their latest financial filing in 2024.

How has Replimune Group's book value per share changed over the last 2 years?

Over the last 2 years, Replimune Group's book value per share changed from 8.71 in 2022 to 6.10 in 2024, a change of -30.0%.


Related Companies

This page (NASDAQ:REPL) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored
The Last Time This Happened, Americans Lost Billions
Wall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...
Banyan Hill Publishing | Sponsored
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...
Behind the Markets | Sponsored
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...
Stansberry Research | Sponsored
A Biotech Power Move? This company is leading the charge in developing advanced antiviral therapies—watch closely!
With a revolutionary antiviral drug, this company is in a great position to build shareholder value as this ti...
Smallcaps Daily | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored